Multimodal Therapy With Metformin, Inositol and Dietary Restriction Improves Insulin Resistance and Endocrine Outcomes in Women With Polyendocrine Metabolic Ovarian Syndrome: A Randomized Controlled Trial.
Noor-Ul-Ain Irfan, Shemaila Saleem, Asma Irfan
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of multimodal therapy (metformin, inositol, and dietary restriction) on insulin resistance and endocrine outcomes in 192 women aged 18-35 with polyendocrine metabolic ovarian syndrome (PMOS). The combination therapy led to the most significant reduction in HOMA-IR by -2.64 and BMI by -2.8 kg/m², indicating improved metabolic and reproductive health.
Key findings
- Combination therapy reduced HOMA-IR by -2.64 (95% CI -2.82 to -2.46, p < 0.001).
- BMI decreased by -2.8 kg/m² (95% CI -3.05 to -2.55, p < 0.001) in the combination group.
- 85.4% of participants in the combination therapy group reported menstrual regularity, the highest among all groups.
Why it matters
The findings suggest that multimodal therapy may offer enhanced benefits for metabolic and reproductive health in women with PMOS, potentially guiding treatment strategies in clinical practice.
What to keep in mind
The study's short follow-up duration limits the assessment of long-term effects.